A team of researchers led by Jorrit Enserink from Oslo University Hospital and Helene Knævelsrud from the University of Oslo has been awarded 40 million NOK from the Research Council of Norway to investigate a fundamental biological question: Can cells remember being starved, and does that memory change how they behave in the future?

The project, called Total Recall (Learn–Recall–Forget: Causal Circuits of Starvation Memory for Population Coherence in Homeostasis and Development), was funded through the prestigious "Toppforskere" programme, which supports research teams with the potential to become world-leading in their field.

Preparedness has become more relevant, along with solutions that can be used in health care as well as in defence – so called dual-use technologies. The European Defence Fund is one of the relevant funding sources for researchers and startups.
At this breakfast event, you will meet researchers and startups developing solutions ranging from protection against microbiological agents to smart textiles

Time and place: May 27, 2026 8:00 AM–10:00 AM, Faros, Toppsenteret, Oslo Science Park, Gaustadalléen 21, Oslo

Visit homepage for programme and registration (uio.no)

A collaborative clinical study (PI: Tormod K. Guren) at OUS reports a long-lasting response to immune check point inhibition in 1 of 8 patients with malignant peripheral nerve sheath tumors (MPNSTs). Multiplex fluorescent immunohistochemistry showed high tumor density of PD-1+CD8+ T cells in tumors with treatment response. In addition, mixed response in a 2^nd patient was associated with high PD-L1 expression.
This study was possible due to a dedicated multidisciplinary collaboration across divisions at OUS, and was recently published in npjPrecision Oncology by Sveen A, Bergsland CH, Niederdorfer B, Berstad AE, Bjerkehagen B, Boye K, Guren TK and Lothe RA.

Precision cancer medicine depends upon getting patients enrolled in the right clinical trials at the right time. A study led by Majd Abdallah and Macha Nikolski (CNRS, University of Bordeaux), in collaboration with Sigve Nakken and Eivind Hovig (Institute for Cancer Research), introduces TrialMatchAI — an AI-powered software system designed to automatically match cancer patients to relevant clinical trials.

Recommended sites for current OUS research news:

From Oslo University Hospital, in Norwegian:
OUS Innsikt – ny forskning, innovasjon og behandling - channel for science communication
More news from OUS (oslo-universitetssykehus.no)

From UiO and centres of excellence (UiO/OUS):
News from the Institute of Clinical Medicine, UiO
CanCell - Centre for Cancer Cell Reprogramming 
Cresco - Centre for Embryology and Healthy Development 
PRIMA - Precision Immunotherapy Alliance - Norwegian version
Hybrid Technology Hub - Centre for Organ on a Chip-Technology

The Innovation Award, organized annually by Inven2, seeks to showcase and reward the most innovative inventions from the brightest researchers. Inven2 aims to bridge the gap between research and the public, transforming cutting-edge ideas into products and services that benefit society.
If you are employed at the University of Oslo, Oslo University Hospital or a hospital in the South-Eastern Norway Regional Health Authority and have an invention, we invite you to participate in the Innovation Award. The winner receives 300 000 NOK, alongside expert guidance and support to help bring the invention to market.